Zydus Cadila gets USFDA nod to market drugs to treat cholesterol and body tissues

AHMEDABAD | MUMBAI | RAJKOT – In a press release submitted to the Exchanges in India, Ahmedabad headquartered and Dr Pankaj Patel led Cadila Healthcare Ltd (Zydus Cadila Group) said of having got US Food & Drugs Administration’s nod to market drug two drugs, one to control cholesterol as well another to treat abnormal hardening of body tissues.

Zydus Cadila has received the final approval from the USFDA to market Atorvastatin Calcium Tablets in the strengths of 10 mg, 20 mg, 40 mg and 80 mg (US RLD – Lipitor) and Dimethyl Fumarate Delayed-Release Capsules, 120mg and 240mg (US RLD – TECFIDERA® capsules).

Atrovastatin Calcium Tablets will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahmedabad, whereas Dimethyl Fumarate Delayed-Release Capsules will be manufactured at the company’s formulations manufacturing facility at SEZ, Ahmedabad.


Atorvastatin is used along with a proper diet to help lower “bad” cholesterol and fats (such as LDL, triglycerides) and raise “good” cholesterol (HDL) in the blood.

It belongs to a group of drugs known as “statins.”

It works by reducing the amount of cholesterol made by the liver. Lowering “bad” cholesterol and triglycerides and raising ”good” cholesterol decreases the risk of heart disease and helps prevent strokes and heart attacks.

Whereas, Dimethyl Fumarate is indicated for the treatment of patients with relapsing forms of multiple sclerosis (abnormal hardening of body tissues).

The group now has 233 approvals and has so far filed over 340 ANDAs since the commencement of the filing process in FY 2003—04.


Announcement from the company of getting USFDA nod to market 2 drugs had hit the exchange, while the trading session was operational on Thursday.

A slight upward momentum was registered, immediately after the announcement hit the exchanges, but failed to seek attention of investors & traders for long time, as the share prices immediately started travelling in RED Zone to end on NEGATIVE counters, while the trading session came to an end on the Indian Bourses on Thursday.